{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-23-000051","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.663610+00:00","generated_at":"2026-06-17T17:52:23.298096+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kiora Pharmaceuticals reports FY2022 net loss of $13.6M; clinical milestones on track for 2023","bullets":["Net loss of $13.6M for FY2022, compared to $13.8M in FY2021; Q4 net loss $2.5M.","Cash and equivalents $6.0M at Dec 31, 2022, plus $1.4M in R&D tax receivables.","KIO-301 Phase 1b ABACUS trial enrollment ongoing; initial results at ARVO April 2023, topline by year-end.","KIO-201 Phase 2 PCED study topline results at ARVO; mean defect size reduction 90% (p<0.003).","KIO-101 Phase 2 trial initiation planned for Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-23-000051","json":"https://secwatch.observer/filing/0001372514-23-000051.json","markdown":"https://secwatch.observer/filing/0001372514-23-000051.md","text":"https://secwatch.observer/filing/0001372514-23-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000051/0001372514-23-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000051/kprx-20230323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T17:52:23.298096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c9514f91dd693d122136b392fc9d7f94f78386b","claim":"KIORA PHARMACEUTICALS INC reported financial results for the fiscal year and fourth quarter ended December 31, 2022.","evidence_excerpt":"On March 23, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the fiscal year and fourth quarter ended December 31, 2022 and an update on clinical development progress.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000051/0001372514-23-000051-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year and fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}